Todd Golde Named Emory’s Newest GRA Fellow, Joins Goizueta Institute @ Emory Brain Health

Emory University has named Todd E. Golde, MD, PhD the new director of the Emory Center for Neurodegenerative Disease (CND) at Goizueta Institute @ Emory Brain Health. Golde will also be named a Georgia Research Alliance (GRA) Neuroscience Distinguished Fellow, with a primary appointment to Emory’s Department of Pharmacology and Chemical Biology and a secondary appointment to the Department of Neurology.

An international expert in the scientific understanding of Alzheimer’s disease and other neurodegenerative diseases, Golde will expand Emory’s translational research for the development of new therapies for neurodegenerative diseases, while facilitating interdisciplinary research in neuroinflammation, bringing the neuroscience and immunology communities.

“Dr. Golde is a world leader in neuroscience research and together at Emory, with our extraordinary faculty in this field, we will be able to make breakthroughs to serve patients and families in innovative ways,” said the President Gregory L. Fenves “I am grateful to the Georgia Research Alliance for its visionary investment in Dr. Golde and for its commitment to bringing outstanding scientists to Georgia.”

Golde’s recruitment to Emory builds on decades of developing neurological disease research programs, including the Emory CND and the Goizueta Alzheimer’s Disease Research Center (GADRC). The Emory CND was established 20 years ago as a cross-departmental translational research program to support faculty members, high-impact team science, core facilities, and unique training and development opportunities professional.

“We are thrilled to announce Dr. Golde’s new role at Emory as Director of the Center for Neurodegenerative Diseases at the Goizeuta Institute @ Emory Brain Health,” said Allan Levey, MD, PhD, Founding Director of the Institute. Goizueta and director of the Emory GADRC.

“His expertise and leadership in the study of Alzheimer’s disease and other neurodegenerative disorders, his innovative science and his commitment to training and career development make him a perfect choice to help us bridge the gap between the fields of neuroscience, immunology and pharmacology. This is an essential part of our efforts to accelerate and expand the team-based science that we urgently need to advance treatments for devastating brain diseases.

“Georgia is fortunate to recruit an enterprising scientist of the caliber of Todd Golde,” says Susan Shows. president of the Georgia Research Alliance. “His career is marked not only by pioneering work in the field of neuroscience, but also by an entrepreneurial spirit and a proven ability to collaborate within and between institutions. He will be a great addition to Emory and the GRA Fellows Academy.

Golde was a professor of neuroscience and neurology at the University of Florida and director of the Evelyn F. and William L. McKnight Brain Institute, Golde was also founding director of the 1Florida Alzheimer’s Disease Research Center, a consortium of institutions in leading Florida backed by the National Institutes of Health (NIH).

Golde’s research lab has produced 310 approximately 43,000-cited publications and has received more than $65 million in NIH grants since 2000. Golde is an inventor on more than 15 patents and patent applications and is a co-founder of two companies of biotechnology.

“Dr. Golde’s remarkable accomplishments and keen interest in advancing new therapeutic strategies to combat Alzheimer’s disease and other neurodegenerative diseases dovetail perfectly with our department’s shared vision for innovation. We are delighted to welcome Dr. Golde to Emory,” said Haian Fu, PhD, professor and chair of the Department of Pharmacology and Chemical Biology at Emory University School of Medicine.

Golde’s research on Alzheimer’s disease helped lay the foundation for the amyloid hypothesis and made major contributions to the understanding of amyloid and tau pathologies, as well as the role of the immune system in the disease. In an effort to develop innovative new therapies to fight Alzheimer’s disease, Golde’s lab is exploring a large number of proteins that accumulate alongside amyloid; investigate the use of antibodies to target psychological stress pathways thought to contribute to AD and many other diseases; and assess ways in which the immune system might be harnessed for beneficial effects in AD.

Established in 1990, the Georgia Research Alliance is a public-private partnership that supports the recruitment of top scientists to Georgia universities, fueling both new discoveries and economic growth. Currently, there are 14 GRA Eminent Scholars and 3 Distinguished Investigators at Emory.

Golde will start at Emory on August 1, 2022.

Comments are closed.